Kerendia is indicated for the treatment of chronic kidney disease (Stages 3 and 4 with albuminuria) associated with type 2 diabetes in adult patients.
Kerendia®▼ (finerenone) Primary Care Resources
What is Kerendia?
A non-steroidal mineralocorticoid receptor antagonist for the treatment of CKD (stages 3 & 4 with albuminuria) associated with T2D.
Protect the Kidneys, Support the Heart
Explore the link between chronic kidney disease and cardiovascular disease, highlighting the importance of early assessment and treatment for optimal patient outcomes.
Identification of Diabetic Kidney Disease (DKD)
A practical guide on identification of diabetic kidney disease in primary care, including:
- UACR testing for early detection
- Management strategies including pharmacotherapy
Kerendia Dosing Guide
A dosing guide to support you with Kerendia treatment.
Who Are Your Kerendia Eligible Patients?
Help your patients at risk of end-stage renal disease.
Hyperkalaemia and Kerendia (Treatment Pauses)
A patient counselling aid for healthcare professionals.
Chronic Kidney Disease Bitesize Videos
Kerendia®▼ (finerenone)
PP-KER-GB-0565, February 2024
Kerendia®▼ (finerenone) Short Videos
PP-KER-GB-0566, March 2024
RP-KER-GB-1106 | January 2025